Ruppé Matt
Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor, characterized by rapid progression, resistance to therapy, and poor survival outcomes. Despite advances in surgical resection, radiation therapy, and chemotherapy, the median survival of GBM patients remains limited to approximately 12–15 months post-diagnosis. Recent research has focused on molecular biomarkers that influence tumor progression and patient prognosis. One such biomarker is RAD51, a crucial protein involved in Homologous Recombination (HR) repair of DNA double-strand breaks. Studies indicate that elevated RAD51 expression is associated with increased tumor aggressiveness and therapy resistance, leading to poorer survival outcomes in GBM patients. RAD51 plays an essential role in maintaining genomic stability by facilitating the error-free repair of DNA damage. It is a key component of the HR repair pathway, allowing cells to recover from DNA damage that would otherwise result in cell death.
PDFShare this article
Journal of Genetics and DNA Research received 3 citations as per Google Scholar report
